Translational Development Acquisition Corp. — fact timeline

Translational Development Acquisition Corp.: Extended the deadline for consummating a business combination from June 24, 2026 to June 24, 2027, with up to twelve monthly extensions (effective 2026-06-17).

“The Extension Amendment extends the date by which the Company must consummate a Business Combination up to twelve (12) times from June 24, 2026 to June 24, 2027, each by an additional one-month period, for a total of twelve (12) months after the Deadline Date, assuming a Business Combination has not occurred.”

Translational Development Acquisition Corp. shareholders approved Adjournment Proposal to adjourn the Meeting if necessary.

“The Adjournment Proposal was approved with the following vote: For Against Abstentions Broker Non-Votes 16,621,609 809,296 0 0”

Translational Development Acquisition Corp. shareholders approved Trust Agreement Amendment Proposal to amend the Trust Agreement to allow extension of Deadline Date with monthly deposits.

“The Trust Agreement Amendment Proposal was approved with the following vote: For Against Abstentions Broker Non-Votes 16,621,609 809,296 0 0”

Translational Development Acquisition Corp. shareholders approved Extension Amendment Proposal to amend the Existing Charter to extend business combination deadline.

“The Extension Amendment Proposal was approved with the following vote: For Against Abstentions Broker Non-Votes 16,621,609 809,296 0 0”

Translational Development Acquisition Corp. amended Trust Agreement Amendment with Continental Stock Transfer & Trust Company valued at The amendment permits the Company to extend the date by which it must consummate an initial business (effective 2026-06-17).

“On June 17, 2026, in connection with the approval by its shareholders of the Trust Agreement Amendment Proposal (as defined below) at the Meeting (as defined below), Translational Development Acquisition Corp., a Cayman Islands exempted company (the “Company”), entered into an amendment (the “Trust Agreement Amendment”) to the Investment Management Trust Agreement, dated as of December 23, 2024 (the “Trust Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as trustee (the “Trustee”). The Trust Agreement Amendment permits the Company to extend the date by which the Company must consummate an initial business combination from June 24, 2026 (the “Deadline Date”) up to twelve (12) times, each by an additional one-month period, to June 24, 2027, by providing five days’ advance notice to the Trustee prior to the applicable Deadline Date and depositing into the Company’s trust account (the “Trust Account”), for each one-month extension, the lesser of $200,”

Translational Development Acquisition Corp. issued 4,657,499 Class A ordinary shares of common stock to TDAC Partners LLC (the Sponsor) for no cash proceeds to the Company.

“On June 12, 2026, Translational Development Acquisition Corp., a Cayman Islands exempted company (the “Company”), issued an aggregate of 4,657,499 Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”), to TDAC Partners LLC (the “Sponsor”), upon the conversion (the “Conversion”) of an equal number of Class B ordinary shares, par value $0.0001 per share (the “Class B Ordinary Shares”), held by the Sponsor.”

Translational Development Acquisition Corp. entered into Business Combination Agreement with Prologium Holding Inc., PLG Merger Sub 1, and PLG Merger Sub 2 valued at approximately $3.8 billion valuation (effective 2026-05-27).

“On May 27, 2026, Translational Development Acquisition Corp., a Cayman Islands exempted company with limited liability (“TDAC”), entered into an Agreement and Plan of Merger (as it may be amended, restated or otherwise modified from time to time, the “Business Combination Agreement”) with Prologium Holding Inc., a Cayman Islands exempted company with limited liability (“ProLogium” or the “Company”), PLG Merger Sub 1, a Cayman Islands exempted company with limited liability and a wholly-owned direct subsidiary of the Company (“Merger Sub 1”), and PLG Merger Sub 2, a Cayman Islands exempted company with limited liability and a wholly-owned direct subsidiary of the Company (“Merger Sub 2” and, together with Merger Sub 1, the “Acquisition Entities”).”

Translational Development Acquisition Corp.: Amended and restated memorandum and articles of association filed and effective (effective 2024-12-20).

“On December 20, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended and Restated Memorandum and Articles of Association ”) with the Cayman Islands Registrar of Companies, which was effective on December 20, 2024.”